Lead Product(s) : TAK-861
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Plans to Rapidly Initiate Global Phase 3 Trials of TAK-861 for Narcolepsy in 2024
Details : TAK-861 is an oral orexin agonist which is being evaluated in phase 2/3 clinical trials for the treatment of patients with Narcolepsy Type 1 & Type 2.
Product Name : TAK-861
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 02, 2024
Lead Product(s) : TAK-861
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : IHL-42X
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Acetazolamide,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Reboxetine Mesylate,Oxybutynin
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep.
Product Name : AD128
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Reboxetine Mesylate,Oxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable